Intakes of fats and types of fatty acids may affect disability severity in multiple sclerosis and neuromyelitis optica spectrum disorder.
Patients with multiple sclerosis who were motivated to remain adherent to treatment experienced overall better outcomes, including low relapse rates.
Barriers to using screening tools included lack of time and lack of insurance compensation.
Data obtained from the iConquerMS network highlight areas of quality of life that affect people with relapsing and progressive forms of MS and provide substantial basis for future research.
Vitamin D deficiency is a risk factor for multiple sclerosis.
The association suggests that caffeine consumption may play a protective role against multiple sclerosis-related disability.
Poor medication timing, incorrect doses, medication disorganization, and under- or over-medication are some of the medication adherence issues that can occur in patients with MS and cognitive symptoms.
Obesity-associated lowering of vitamin D levels may not mediate the putative causal relationship between obesity and multiple sclerosis.
Authors describe 2 case reports of MS in the pediatric population after administration of HPV vaccination.
The EFFECT study compared the efficacy of dimethyl fumarate vs other disease-modifying therapies, including fingolimod and glatiramer acetate in patients with relapsing-remitting multiple sclerosis.
A significant unmet need remains for an effective, well-tolerated, and convenient treatment for patients with progressive forms of MS.
The post-hoc analysis compared 6-month confirmed disability progression using patient data from PRISMS-2.
The randomized, double-blind PARADIGM study compared the safety and efficacy of fingolimod and interferon β-1a in teens with relapsing-remitting MS.
Application of technology developed in the gaming and computer control industry offers the opportunity to create new metrics with greater sensitivity and reproducibility.
Study authors emphasize the rebound relapse phenomenon as a potential complication in the safety of fingolimod.
A 55-year-old woman with multiple sclerosis and no history of thyroid disease developed lab abnormalities suggestive of thyrotoxicosis on routine testing.
Relapsing-Remitting Multiple Sclerosis: Maintaining No Evidence of Disease Activity With NatalizumabFebruary 01, 2018
Researchers aimed to determine the proportion of patients with early relapsing-remitting multiple sclerosis treated with natalizumab who achieve no evidence of disease activity at year 2.
Ozanimod decreased both T2 and T1 brain lesions and brain volume loss in patients with relapsing multiple sclerosis.
CRISP will determine the suitability of clozapine and risperidone as a treatment for progressive multiple sclerosis.
Researchers examined patients' disease course and the number of clinical attacks to determine the safety and efficacy of intravenous cladribine.
Neurology Advisor Articles
- 5 Key Findings Presented at 2018 Parkinson Disease Conference
- Parkinson Disease and the Gut: Treatment Potential Abounds
- Managing Comorbid Migraine and Mood Disorders: A Synergistic Approach
- Stroke-Code Patients With Low NIHSS Score, No Acute Imaging Findings Often Misdiagnosed
- Ethical Challenges of Nusinersen: Considerations When Counseling on Treatment
- Gender and Multiple Sclerosis: How It Influences Prognosis and Future Treatment
- Drug Prices Increase More Than Expected After Shortages
- Potentially Inappropriate Opioid Prescribing Tied to Overdose
- Loss of Function Variants in LRKK1 and LRKK2 Not Linked to Parkinson Disease
- Scribes Improve Physician Workflow, Patient Interaction